Montesano Teresa, Durante Cosimo, Attard Marco, Crocetti Umberto, Meringolo Domenico, Bruno Rocco, Tumino Salvatore, Rubello Domenico, Al-Nahhas Adil, Colandrea Marzia, Maranghi Marianna, Travascio Laura, Ronga Giuseppe, Torlontano Massimo
Dipartimento di Scienze Cliniche, Università "La Sapienza", Viale del Policlinico, 155, 00161 Roma, Italy.
Biomed Pharmacother. 2007 Sep;61(8):468-71. doi: 10.1016/j.biopha.2007.04.001. Epub 2007 May 22.
Recombinant human TSH (rhTSH) has been recently suggested for radioiodine ablation in patients with differentiated thyroid cancer (DTC). To date, studies are still not available about the effectiveness of rhTSH stimulation depending on the age, since serum TSH clearance may be different in younger and in older patients. The aim of this study was to investigate the influence of age to serum TSH levels after rhTSH stimulation and thyroid hormone withdrawal (THW). We retrospectively evaluated two groups of consecutive DTC patients: group 1 (311 patients, age 49.0+/-13.6 years, ranging 15-86) underwent rhTSH stimulation 6-12 months after thyroid ablation (rhTSH-group); group 2 (84 patients, age 46.9+/-13.5 years, ranging 20-77) was followed by THW (THW-group). The influence of age, gender, body mass index and body surface area to serum TSH levels were evaluated in both groups. RhTSH-group: on day 5 (d5), TSH levels were 32.7+/-21.4 microU/ml (range 0.8-136.6). By univariate analysis, d5-TSH was positively related to age (r=0.27, p=0.0001) and no correlations were found with the other parameters. At multivariate analysis, both age and gender (female) were independently associated with d5-TSH levels. THW-group: after thyroid hormone withdrawal, TSH levels were 71.1+/-36.4 microU/ml (range 8.5-200). At univariate analysis, only age was significantly and negatively related to serum TSH levels (r=-0.31, p=0.004). Our data indicate that age and gender seem to positively influence serum TSH levels after rhTSH stimulation. An opposite effect of age on serum TSH levels has been observed after THW. Therapeutic implications ((131)I-treatment) of these findings have to be better investigated in prospective studies.
重组人促甲状腺激素(rhTSH)最近被推荐用于分化型甲状腺癌(DTC)患者的放射性碘消融治疗。迄今为止,尚无关于rhTSH刺激有效性随年龄变化的研究,因为年轻患者和老年患者的血清促甲状腺激素清除率可能不同。本研究的目的是探讨年龄对rhTSH刺激及甲状腺激素撤停(THW)后血清促甲状腺激素水平的影响。我们回顾性评估了两组连续的DTC患者:第1组(311例患者,年龄49.0±13.6岁,范围15 - 86岁)在甲状腺消融术后6 - 12个月接受rhTSH刺激(rhTSH组);第2组(84例患者,年龄46.9±13.5岁,范围20 - 77岁)采用甲状腺激素撤停(THW组)。评估了两组中年龄、性别、体重指数和体表面积对血清促甲状腺激素水平的影响。rhTSH组:在第5天(d5),促甲状腺激素水平为32.7±21.4 μU/ml(范围0.8 - 136.6)。单因素分析显示,d5时的促甲状腺激素与年龄呈正相关(r = 0.27,p = 0.0001),与其他参数无相关性。多因素分析显示,年龄和性别(女性)均与d5时的促甲状腺激素水平独立相关。THW组:甲状腺激素撤停后,促甲状腺激素水平为71.1±36.4 μU/ml(范围8.5 - 200)。单因素分析显示,仅年龄与血清促甲状腺激素水平呈显著负相关(r = -0.31,p = 0.004)。我们的数据表明,年龄和性别似乎对rhTSH刺激后的血清促甲状腺激素水平有正向影响。甲状腺激素撤停后观察到年龄对血清促甲状腺激素水平有相反的影响。这些发现的治疗意义((131)I治疗)必须在前瞻性研究中进行更好的研究。